Track topics on Twitter Track topics that are important to you
DeuteRx LLC granted Poxel SA exclusive global rights to DRX065, a Phase I candidate that Poxel intends to develop for nonalcoholic steatohepatitis (NASH).
Presentation to be webcast on March 19 at 5:20 p.m. ET DeuteRx LLC, a clinical stage biopharmaceutical company dedicated to improving racemic drugs, today announced tha...
Poxel acquires exclusive, worldwide ownership to DRX-065 (deuterium-stabilized R-pioglitazone), a clinical stage program being pursued for the treatment of NASH ...
DeuteRx is pioneering âdeuterium-enabled chiral switchingâ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) s...
DeuteRx has pioneered âdeuterium-enabled chiral switchingâ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) s...
We have published hundreds of DeuteRx LLC news stories on BioPortfolio along with dozens of DeuteRx LLC Clinical Trials and PubMed Articles about DeuteRx LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DeuteRx LLC Companies in our database. You can also find out about relevant DeuteRx LLC Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...